BAIT 719
Alternative Names: BAIT-719Latest Information Update: 08 Dec 2023
At a glance
- Originator Astante Therapeutics
- Class Antineoplastics; Glycoconjugates; Imidazoles; Quinolines
- Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Nov 2023 BAIT 719 is available for licensing as of 08 Nov 2023. https://astantetherapeutics.com/
- 20 Sep 2023 Preclinical trials in Solid tumours in USA (unspecified route) prior to September 2023
- 20 Sep 2023 Efficacy and adverse events data from a Preclinical studies in Melanoma presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference(CRI-ENCI-AACR-2023)